Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 10
1996 15
1997 15
1998 17
1999 33
2000 35
2001 53
2002 80
2003 66
2004 77
2005 86
2006 72
2007 82
2008 108
2009 132
2010 134
2011 143
2012 136
2013 153
2014 149
2015 147
2016 151
2017 120
2018 115
2019 116
2020 118
2021 127
2022 114
2023 85
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

2,483 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Sclerosis.
Reich DS, Lucchinetti CF, Calabresi PA. Reich DS, et al. N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483. N Engl J Med. 2018. PMID: 29320652 Free PMC article. Review. No abstract available.
Pregnancy and multiple sclerosis: an update.
Varytė G, Arlauskienė A, Ramašauskaitė D. Varytė G, et al. Curr Opin Obstet Gynecol. 2021 Oct 1;33(5):378-383. doi: 10.1097/GCO.0000000000000731. Curr Opin Obstet Gynecol. 2021. PMID: 34310364 Free PMC article. Review.
Teriflunomide and fingolimod are not recommended during breastfeeding, however, glatiramer acetate and IFN-beta are considered to be safe. SUMMARY: The evidence of potential fetotoxicities and adverse pregnancy outcomes associated with DMTs is increasing, although m …
Teriflunomide and fingolimod are not recommended during breastfeeding, however, glatiramer acetate and IFN-beta are considered …
Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
Stamatellos VP, Papazisis G. Stamatellos VP, et al. Curr Rev Clin Exp Pharmacol. 2023;18(1):39-50. doi: 10.2174/2772432817666220412110720. Curr Rev Clin Exp Pharmacol. 2023. PMID: 35418296 Review.
CONCLUSION: Data for oral (Sphingosine 1-phosphate (S1P) receptor modulators, Fumarates, Teriflunomide, Cladribine), injectables (Interferons, Glatiramer acetate, Ofatumumab), and infusion therapies (Natalizumab, Ocrelizumab, Alemtuzumab) are presented....
CONCLUSION: Data for oral (Sphingosine 1-phosphate (S1P) receptor modulators, Fumarates, Teriflunomide, Cladribine), injectables (Interferon …
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
EXPOSURES: The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or alemtuzumab. After propensity-score matching, 1555 patients were included (last follow-up, February 14, 2017). ...The probability of conversi …
EXPOSURES: The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or a …
Pregnancy and fetal outcomes following maternal exposure to glatiramer acetate in all three trimesters of pregnancy.
Kaplan S, Zeygarnik M, Stern T, Hellwig K. Kaplan S, et al. Eur J Neurol. 2023 Dec;30(12):3890-3895. doi: 10.1111/ene.16036. Epub 2023 Aug 24. Eur J Neurol. 2023. PMID: 37565380
In this analysis, we assessed pregnancy and fetal outcomes following maternal glatiramer acetate (GA) exposure in all three trimesters among cases reported between 1997 and 2020. ...
In this analysis, we assessed pregnancy and fetal outcomes following maternal glatiramer acetate (GA) exposure in all three tr …
Nicolau syndrome caused by Glatiramer.
Ciprian S, Lava SAG, Milani GP, Bianchetti MG, Consolascio D, Lardelli PF. Ciprian S, et al. Mult Scler Relat Disord. 2022 Jan;57:103365. doi: 10.1016/j.msard.2021.103365. Epub 2021 Nov 2. Mult Scler Relat Disord. 2022. PMID: 35158471 Free article.
Injection-site reactions to glatiramer are common and include erythema, pruritus, pain, or induration. Additionally, the present systematic review of the literature documents 20 cases of Nicolau syndrome following glatiramer, a rare but potentially severe skin react …
Injection-site reactions to glatiramer are common and include erythema, pruritus, pain, or induration. Additionally, the present syst …
Glatiramer acetate: A complex drug beyond biologics.
Rocco P, Eberini I, Musazzi UM, Franzè S, Minghetti P. Rocco P, et al. Eur J Pharm Sci. 2019 May 15;133:8-14. doi: 10.1016/j.ejps.2019.03.011. Epub 2019 Mar 19. Eur J Pharm Sci. 2019. PMID: 30902653 Free article. Review.
In the case of Non Biological Complex Drugs (NBCDs), complexity may arise either from the active substance, as in the case of glatiramer acetate, or from other sources, such as the formulation, as in the case of liposomes. In this paper, the case of glatiramer
In the case of Non Biological Complex Drugs (NBCDs), complexity may arise either from the active substance, as in the case of glatiramer
Glatiramer acetate for multiple sclerosis.
La Mantia L, Munari LM, Lovati R. La Mantia L, et al. Cochrane Database Syst Rev. 2010 May 12;(5):CD004678. doi: 10.1002/14651858.CD004678.pub2. Cochrane Database Syst Rev. 2010. PMID: 20464733 Review.
OBJECTIVES: To verify the clinical efficacy of glatiramer acetate in the treatment of MS patients with relapsing remitting (RR) and progressive (P) course. ...Local injection-site reactions were observed in up to a half of patients treated with glatiramer
OBJECTIVES: To verify the clinical efficacy of glatiramer acetate in the treatment of MS patients with relapsing remitting (RR …
An update on combination therapies for multiple sclerosis: where are we now?
Sorensen PS, Magyari M, Sellebjerg F. Sorensen PS, et al. Expert Rev Neurother. 2023 Jul-Dec;23(12):1173-1187. doi: 10.1080/14737175.2023.2289572. Epub 2023 Dec 15. Expert Rev Neurother. 2023. PMID: 38058171 Review.
EXPERT OPINION: Combination of two platform therapies (Interferon-beta or glatiramer acetate) was without additional effect. Clinical trials with add-on, often applying repurposed drugs (e.g. simvastatin, atorvastatin, minocycline, estriol, cyclophosphamide, azathio …
EXPERT OPINION: Combination of two platform therapies (Interferon-beta or glatiramer acetate) was without additional effect. C …
2,483 results